The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Novel estrogen receptor beta agonist S-equol decreases tumor proliferation in patients with triple negative breast cancer (TNBC).
 
Kate Ida Lathrop
Research Funding - Ausio Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Encore Clinical
 
Virginia G. Kaklamani
Honoraria - AstraZeneca; Celgene; Eisai; Genentech; Genomic Health; Novartis; Pfizer; Puma Biotechnology
Consulting or Advisory Role - Amgen; AstraZeneca; Athenex; Celldex; Eisai; Puma Biotechnology
Speakers' Bureau - Celgene; Eisai; Genentech; Genomic Health; Novartis; Pfizer; Puma Biotechnology
Research Funding - Eisai
 
Andrew Jacob Brenner
Leadership - NanoTX
Stock and Other Ownership Interests - NanoTX
Honoraria - Vascular Biogenics
Consulting or Advisory Role - NanoTX; Vascular Biogenics
Research Funding - miRNA Therapeutics (Inst); Threshold Pharmaceuticals; Vascular Biogenics
Patents, Royalties, Other Intellectual Property - I have intellectual property interest in NanoTx Therapeutics
Travel, Accommodations, Expenses - Vascular Biogenics
 
Rong Li
Consulting or Advisory Role - Clayton Biotech; Clayton Biotech
Research Funding - Ausio Pharmaceuticals; Ausio Pharmaceuticals
 
Alia Nazarullah
No Relationships to Disclose
 
Sarah Hackman
No Relationships to Disclose
 
Courtney Thomas
No Relationships to Disclose
 
Jonathan Gelfond
No Relationships to Disclose
 
Marisa Rodriguez
No Relationships to Disclose
 
Richard Elledge
No Relationships to Disclose